PegBio 派格生物 IPO: A (Supposedly) Straightforward GLP-1 Challenger Story
PegBio plans to raise $100m in Hong Kong IPO, with focus on core product PB-117 as a GLP-1 challenger, but concerns arise upon closer examination...
423 Views
Pre-IPO PegBio Co., Ltd. (PHIP Updates) - Some Points Worth the Attention
Market expectations for PegBio's GLP-1 pipelines are changing, casting doubt on valuation. PB-119 faces tough competition in a crowded market. We...
447 Views
Hong Kong: IPO SPOTLIGHT - OVERVIEW 2025
Hong Kong is the top global destination for IPOs in 2025, with over HK $280 billion raised so far. Large scale A+H dual listings have surged this...
573 Views
APAC Healthcare Weekly (November 16) – Leads Bio, Henlius Bio, Otsuka, ABL Bio, Boryung, Eubiologics
Henlius got FDA approval for Perjeta biosimilar. Otsuka reports positive Phase 3 trial result for sibepernlimab. ABL Bio signed deal with Lilly....
445 Views
Innogen (银诺医药) IPO: Fairly Valued at Best and Lack of Institutional Interests
China biotech company Innogen launches IPO in Hong Kong to raise at least $88 million, with a demanding valuation and lack of institutional...
573 Views